Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

Zydus Cadila gets USFDA nod to market generic seizures treatment drug

The company has received the final approval from the United States Food and Drug Administration (USFDA) to market Clobazam tablets in the strengths of 10 mg and 20 mg, in the American market, Zydus Cadila said in a statement.

October 23, 2018 / 02:43 PM IST
Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

Drug firm Zydus Cadila on Tuesday said it has received final nod from the US health regulator to market generic Clobazam tablets used for treatment of seizures caused by a paediatric epilepsy syndrome.

The company has received the final approval from the United States Food and Drug Administration (USFDA) to market Clobazam tablets in the strengths of 10 mg and 20 mg, in the American market, Zydus Cadila said in a statement.

The product is a generic version of Onfi tablets, it added.

The tablets "will be manufactured at the group's formulations manufacturing facility at Special Economic Zone (SEZ), Ahmedabad," Zydus Cadila said.

Clobazam is used in combination with other medications to treat seizures caused by a paediatric epilepsy syndrome (Lennox-Gastaut syndrome) that also causes developmental and behavioural problems, it added.

The group now has 224 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.

Shares of Cadila Healthcare, the listed entity of the group, were today trading at Rs 369.80 per scrip on BSE, down 0.98 percent from its previous close.

PTI
first published: Oct 23, 2018 02:38 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347